The decision by the UK Competition and Markets Authority to impose a fine of almost £90m ($113m) on Pfizer and Flynn Pharma for charging “excessive and unfair” prices for the anti-epileptic drug, phenytoin sodium capsules, should serve as a warning to other companies that may be considering significant price increases on marketed drugs.
It is also likely to set alarm bells ringing among the other firms that are currently under investigation by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?